Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3010% below fair value
$5.70+0.07 (+1.24%)
Close on Nov 17, 2026Market cap $740.90MP/E –Yield –
Cytek Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Cytek Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $37.26M, down 2.3% year over year. For fiscal 2025 it was $36.47M, down 7.4% from the year before. The highest annual figure on record is $44.15M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.47M | -7.4% |
| FY2024 | Dec 31, 2024 | $39.40M | -10.8% |
| FY2023 | Dec 31, 2023 | $44.15M | +26.7% |
| FY2022 | Dec 31, 2022 | $34.86M | +42.6% |
| FY2021 | Dec 31, 2021 | $24.44M | +78.5% |
| FY2020 | Dec 31, 2020 | $13.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.74M | +10.4% |
| Q1 FY2026 | Mar 31, 2026 | $9.60M | -1.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.96M | -7.8% |
| Q3 FY2025 | Sep 30, 2025 | $8.96M | -9.4% |
| Q2 FY2025 | Jun 30, 2025 | $8.83M | -11.7% |
| Q1 FY2025 | Mar 31, 2025 | $9.73M | -0.7% |
| Q4 FY2024 | Dec 31, 2024 | $9.72M | -10.5% |
| Q3 FY2024 | Sep 30, 2024 | $9.88M | -11.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.00M | -17.6% |
| Q1 FY2024 | Mar 31, 2024 | $9.80M | -1.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.87M | +11.5% |
| Q3 FY2023 | Sep 30, 2023 | $11.17M | +29.1% |
| Q2 FY2023 | Jun 30, 2023 | $12.14M | +43.9% |
| Q1 FY2023 | Mar 31, 2023 | $9.97M | +24.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.75M | +37.7% |
| Q3 FY2022 | Sep 30, 2022 | $8.65M | +42.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.44M | +36.2% |
| Q1 FY2022 | Mar 31, 2022 | $8.03M | +57.5% |
| Q4 FY2021 | Dec 31, 2021 | $7.08M | +61.4% |
| Q3 FY2021 | Sep 30, 2021 | $6.08M | +80.0% |
| Q2 FY2021 | Jun 30, 2021 | $6.19M | +112.4% |
| Q1 FY2021 | Mar 31, 2021 | $5.09M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.38M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.92M | – |
See a number that looks wrong?